Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-7 + IL-15 + iMSCs
- Development stage
- Preclinical
- Lead developer
- Ernexa Therapeutics
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intraperitoneal, Intravenous
01
Overview
IL-7 + IL-15 + iMSCs (also known as ERNA-101) is a preclinical cell-based biologic therapy being developed by Ernexa Therapeutics. The therapy consists of induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) engineered to secrete the pro-inflammatory cytokines interleukin-7 (IL-7) and interleukin-15 (IL-15). These synthetic, allogeneic cells are designed to home to the tumor microenvironment (TME) and deliver high local concentrations of cytokines, thereby activating and expanding T cells and natural killer (NK) cells in situ. Additionally, the therapy promotes the polarization of immunosuppressive M2-like macrophages toward a pro-inflammatory M1-like phenotype, effectively converting 'cold' tumors into 'hot' ones. ERNA-101 is primarily being investigated for the treatment of advanced solid tumors, including platinum-resistant ovarian cancer and triple-negative breast cancer, with potential applications in hematological malignancies.
- Other names
- IL-7/IL-15-iMSCsGene-modified iPSC-derived MSCs
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL7R (Interleukin-7 Receptor)
Beyond the preview
Go deeper on IL-7 + IL-15 + iMSCs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-7 + IL-15 + iMSCs.